Malaria epidemiological surveys were conducted in 16 villages along the Indo-Bangladesh border in Tripura, northeastern India. Insecticide resistance among malaria vectors and chloroquine resistance in the parasite were also studied along with monitoring of vector density using light traps. The epidemiological data indicated that malaria incidence was highest during June-July and lowest during ...

Malaria kills over a million people each year. The loss of chloroquine due to the spread of parasite resistance is largely responsible for the resurgence of malaria. A new class of antimalarial drugs called artemisinins are available, but are unaffordable to most people in malaria-endemic countries and may quickly face the same fate as chloroquine unless they are combined with a partner drug. S...

Suspicion of failure in the effectiveness artemisinin-based combination therapies (currently first-line treatment malaria, worldwide) is leading to unofficial use alternative antimalarials, including chloroquine and sulfadoxine/pyrimethamine, across northern Nigeria. To facilitate evidence-based resistance management, antimalarial mutations were investigated Plasmodium falciparum multidrug resi...

Pyronaridine and artesunate have been shown to be effective in falciparum malaria treatment. However, pyronaridine is rarely used in Hainan Island clinically, and artesunate is not widely used as a therapeutic agent. Instead, conventional antimalarial drugs, chloroquine and piperaquine, are used, explaining the emergence of chloroquine-resistant Plasmodium falciparum. In this article, we invest...

Antimalarial drug resistance remains a major obstacle in malaria control. Evidence from Southeast Asia shows that resistance to artemisinin combination therapy (ACT) is inevitable. Ethnopharmacological studies have confirmed the efficacy of curcumin against Plasmodium spp. Drug interaction assays between curcumin/piperine/chloroquine and curcumin/piperine/artemisinin combinations and the potent...

The spread of chloroquine-resistant Plasmodium falciparum in most counmes in sub-saharan Africa has raised an urgent need to determine what alternative antimalarial drug should replace chloroquine for the first-line oral treatment of acute uncomplicated falciparum malaria. The drug must satisfy the following requirements to be a viable option in Africa: high and rapid clinical efficacy, short t...

www.sciencemag.org SCIENCE VOL 333 5 AUGUST 2011 663 COVER A pair of chemical compounds (light blue and purple) target wild-type and mutant forms of the Plasmodium falciparum chloroquine resistance transporter, which mediates the parasite’s (yellow) resistance to the widely used antimalarial drug. Using high-throughput chemical and genetic analyses, Yuan et al. identify potential new antimalari...

In Uganda, artemether-lumefantrine was introduced as an artemisinin-based combination therapy (ACT) for malaria in 2006. We have previously reported a moderate decrease ex vivo efficacy of lumefantrine Northern where we also detected artemisinin-resistant Plasmodium falciparum. Therefore, it is necessary to search candidate partner alternatives ACT. Here, investigated susceptibility four ACT dr...

mouse erythrocytes accumulated more than half as much mefloquine as infected erythrocytes. The process of accumulation was not stimulated by providing glucose as a substrate, and it was not inhibited in infected erythrocytes by azide, iodoacetate, or incubation at 2°C. Although mefloquine was accumulated more effectively than chloroquine by uninfected erythrocytes and by erythrocytes infected w...